MiNK Therapeutics (INKT)

• Market cap: $60.2M
• 1 day: -8.71%
• 5 days: -19.64%
• 1 month: 104.33%
• 3 months: 102.68%
• 6 months: 64.85%
• Year to date: 49.50%
• 1 year: 60.64%
• 5 years: -87.42%
• 10 years: -87.42%
• Sector: Healthcare
• Industry: Biotechnology

About: MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.

Employees: 23

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0.46% less ownership

Funds ownership: 2.04% [Q4 2024] → 1.59% (-0.46%) [Q1 2025]

4% less capital invested

Capital invested by funds: $565K [Q4 2024] → $544K (-$20.7K) [Q1 2025]

26% less funds holding

Funds holding: 23 [Q4 2024] → 17 (-6) [Q1 2025]

75% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 8

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 15

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $35 132% upside
• Avg. target: $35 132% upside
• High target: $35 132% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

HC Wainwright & Co. Emily Bodnar

132% upside $35

Neutral Downgraded

15 Jul 2025